These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 6766563

  • 1. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Yamada K, Kawashima K, Kato Y, Morishima Y, Tanimoto M, Ohno R.
    Recent Results Cancer Res; 1980; 70():219-29. PubMed ID: 6766563
    [Abstract] [Full Text] [Related]

  • 2. Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K, Yamada K, Uzuka Y, Maekawa T, Takaku F, Shimoyama M, Ogawa M, Amaki I, Osamura S, Ito M, Sakai Y, Oguro M, Hattori K, Hoshino A, Hirota Y, Ohta K, Nakamura T, Masaoka T, Kimura I, Ichimaru M.
    Recent Results Cancer Res; 1981; 76():232-40. PubMed ID: 7232852
    [Abstract] [Full Text] [Related]

  • 3. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
    Yoshida T, Nakamura S, Ohtake S, Ito K, Kobayashi K, Kanno M, Hirai J, Tachimori K, Matsuda T.
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
    Maehara Y, Kusumoto T, Sakaguchi Y, Kusumoto H, Anai H, Sugimachi K.
    Anticancer Res; 1989 Jun; 9(1):41-4. PubMed ID: 2705754
    [Abstract] [Full Text] [Related]

  • 5. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Maehara Y, Kusumoto T, Kusumoto H, Anai H, Sugimachi K.
    Chemotherapy; 1989 Jun; 35(3):181-6. PubMed ID: 2766858
    [Abstract] [Full Text] [Related]

  • 6. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus.
    Nakamura K, Eizuru Y, Kumura K, Minamishima Y.
    J Med Virol; 1990 Jun; 31(2):141-7. PubMed ID: 1696958
    [Abstract] [Full Text] [Related]

  • 7. Clinical use of intermediate to high dose of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in children with acute leukemia.
    Takashima Y.
    J Clin Pharmacol; 1988 Apr; 28(4):356-62. PubMed ID: 3164731
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K, Ohno R, Amaki I, Hattori K, Hirota Y, Hoshino A, Ichimaru M, Ito M, Kimura I, Maekawa T.
    Med Oncol Tumor Pharmacother; 1986 Apr; 3(1):15-24. PubMed ID: 3702507
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, Johno I, Akiyama Y.
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [Abstract] [Full Text] [Related]

  • 11. Effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on blast progenitors of acute myeloblastic leukemia.
    Nara N, Tohda S, Suzuki T, Nagata K, Yamashita Y, Imai Y, Maruyama Y, Tomiyama J.
    Cancer Res; 1990 Dec 01; 50(23):7587-92. PubMed ID: 2253209
    [Abstract] [Full Text] [Related]

  • 12. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP, Preisler HD, Slocum H, Rustum YM.
    Cancer Res; 1982 Apr 01; 42(4):1587-94. PubMed ID: 6949642
    [Abstract] [Full Text] [Related]

  • 13. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)].
    Takenaka T, Kimura K.
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec 20; 20(10):2322-8. PubMed ID: 3831176
    [No Abstract] [Full Text] [Related]

  • 14. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J, Kataoka T, Tsukagoshi S, Sakurai Y, Shibukawa M, Kobayashi H.
    Cancer Res; 1981 Jun 20; 41(6):2501-6. PubMed ID: 7237444
    [Abstract] [Full Text] [Related]

  • 15. Clincal pharmacology of O2,2'-cyclocytidine.
    Rodriguez DH, Loo TL, Bodey GP, Freireich EJ.
    Clin Pharmacol Ther; 1975 Jan 20; 17(1):66-72. PubMed ID: 1173058
    [Abstract] [Full Text] [Related]

  • 16. Cytokinetic study on the effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on murine leukemic cells L 1210: a comparison with the effects of 1-beta-D-arabinofuranosylcytosine.
    Maruo N, Horiuchi H, Nakabo T, Kondo M, Nakamura T.
    Hematol Oncol; 1985 Jan 20; 3(1):39-48. PubMed ID: 2580770
    [Abstract] [Full Text] [Related]

  • 17. Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
    Ueda T, Nakamura T, Kagawa D, Uchida M, Domae N, Sugiyama M, Ueda Y, Sasada M, Uchino H.
    Cancer Chemother Pharmacol; 1989 Jan 20; 24(6):371-5. PubMed ID: 2791191
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of acute leukemia with newly synthesized N4-behenoyl-l-beta-D-arabinofuranosylcytosine (BH-AC) (author's transl)].
    Sueyama H, Oguro M, Takagi T.
    Rinsho Ketsueki; 1981 Jul 20; 22(7):1109-15. PubMed ID: 7328768
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
    Sampi K, Sakurai M, Kaneko Y, Hattori M.
    Oncology; 1986 Jul 20; 43(1):18-22. PubMed ID: 3455751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.